Srinivasa Rao
Yeshiva University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Srinivasa Rao.
Journal of Medicinal Chemistry | 2013
Ravinder Reddy Kondreddi; Jan Jiricek; Srinivasa Rao; Suresh B. Lakshminarayana; Luis R. Camacho; Ranga Rao; Maxime Herve; Pablo Bifani; Ngai Ling Ma; Kelli Kuhen; Anne Goh; Arnab K. Chatterjee; Thomas Dick; Thierry T. Diagana; Ujjini H. Manjunatha; Paul W. Smith
Indole-2-carboxamides have been identified as a promising class of antituberculosis agents from phenotypic screening against mycobacteria. One of the hits, indole-2-carboxamide analog (1), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high mouse liver microsomal clearance, and low aqueous solubility. Structure-activity relationship studies revealed that attaching alkyl groups to the cyclohexyl ring significantly improved Mtb activity but reduced solubility. Furthermore, chloro, fluoro, or cyano substitutions on the 4- and 6-positions of the indole ring as well as methyl substitution on the cyclohexyl ring significantly improved metabolic stability. 39 and 41, the lead candidates, displayed improved in vitro activity compared to most of the current standard TB drugs. The low aqueous solubility could not be mitigated because of the positive correlation of lipophilicity with Mtb potency. However, both compounds displayed favorable oral pharmacokinetic properties in rodents and demonstrated in vivo efficacy. Thus, indole-2-carboxamides represent a promising new class of antituberculosis agents.
Antimicrobial Agents and Chemotherapy | 2013
Goran Biuković; Sandip Basak; Malathy Sony Subramanian Manimekalai; Sankaranarayanan Rishikesan; Manfred Roessle; Thomas Dick; Srinivasa Rao; Cornelia Hunke; Gerhard Grüber
ABSTRACT The subunit ε of bacterial F1FO ATP synthases plays an important regulatory role in coupling and catalysis via conformational transitions of its C-terminal domain. Here we present the first low-resolution solution structure of ε of Mycobacterium tuberculosis (Mtε) F1FO ATP synthase and the nuclear magnetic resonance (NMR) structure of its C-terminal segment (Mtε103–120). Mtε is significantly shorter (61.6 Å) than forms of the subunit in other bacteria, reflecting a shorter C-terminal sequence, proposed to be important in coupling processes via the catalytic β subunit. The C-terminal segment displays an α-helical structure and a highly positive surface charge due to the presence of arginine residues. Using NMR spectroscopy, fluorescence spectroscopy, and mutagenesis, we demonstrate that the new tuberculosis (TB) drug candidate TMC207, proposed to bind to the proton translocating c-ring, also binds to Mtε. A model for the interaction of TMC207 with both ε and the c-ring is presented, suggesting that TMC207 forms a wedge between the two rotating subunits by interacting with the residues W15 and F50 of ε and the c-ring, respectively. T19 and R37 of ε provide the necessary polar interactions with the drug molecule. This new model of the mechanism of TMC207 provides the basis for the design of new drugs targeting the F1FO ATP synthase in M. tuberculosis.
Journal of Medicinal Chemistry | 2015
Renier van der Westhuyzen; Susan Winks; Colin R. Wilson; Grant Boyle; Richard K. Gessner; Candice Soares de Melo; Dale Taylor; Carmen de Kock; Mathew Njoroge; Christel Brunschwig; Nina Lawrence; Srinivasa Rao; Frederick A. Sirgel; Paul D. van Helden; Ronnett Seldon; Atica Moosa; Digby F. Warner; Luca Arista; Ujjini H. Manjunatha; Paul W. Smith; Leslie J. Street; Kelly Chibale
High-throughput screening of a library of small polar molecules against Mycobacterium tuberculosis led to the identification of a phthalimide-containing ester hit compound (1), which was optimized for metabolic stability by replacing the ester moiety with a methyl oxadiazole bioisostere. A route utilizing polymer-supported reagents was designed and executed to explore structure-activity relationships with respect to the N-benzyl substituent, leading to compounds with nanomolar activity. The frontrunner compound (5h) from these studies was well tolerated in mice. A M. tuberculosis cytochrome bd oxidase deletion mutant (ΔcydKO) was hyper-susceptible to compounds from this series, and a strain carrying a single point mutation in qcrB, the gene encoding a subunit of the menaquinol cytochrome c oxidoreductase, was resistant to compounds in this series. In combination, these observations indicate that this novel class of antimycobacterial compounds inhibits the cytochrome bc1 complex, a validated drug target in M. tuberculosis.
Bioorganic & Medicinal Chemistry Letters | 1997
Paul A. Wender; Daesung Lee; Tapan K. Lal; Susan Band Horwitz; Srinivasa Rao
Abstract Two new taxol analogs 6 and 10 have been prepared from baccatin III (1) and taxol (7a), respectively. Like taxol, both compounds were found to promote microtubule formation and stabilization, although they were less active than taxol. Both 6 and 10 exhibited cytotoxicity against J774.2 cells; 6 was ∼60-fold less active and 10 was ∼15-fold less active.
Journal of Biological Chemistry | 1994
Srinivasa Rao; N. E. Krauss; J. M. Heerding; C. S. Swindell; I. Ringel; George A. Orr; Susan Band Horwitz
Journal of Medicinal Chemistry | 1995
Iwao Ojima; Olivier Duclos; György Dormán; Bruno Simonot; Glenn D. Prestwich; Srinivasa Rao; Keith A. Lerro; Susan Band Horwitz
Journal of Medicinal Chemistry | 1993
Joan M. Carboni; Vittorio Farina; Srinivasa Rao; Sheila I. Hauck; Susan Band Horwitz; Israel Ringel
Biochemistry | 2001
Srinivasa Rao; Fredrik Åberg; Edward Nieves; Susan Band Horwitz; George A. Orr
Journal of Medicinal Chemistry | 1994
Charles S. Swindell; Julia M. Heerding; Nancy Krauss; Susan Band Horwitz; Srinivasa Rao; Israel Ringel
Methods in Enzymology | 1998
George A. Orr; Srinivasa Rao; Charles S. Swindell; David G. I. Kingston; Susan Band Horwitz